2026年3月10日盘后,君实生物(SH688180)发布公告,披露了公司控股股东、实际控制人之一兼董事长熊俊增持计划的进展。根据公告,熊俊自2025年4月启动的亿元级增持计划已临近到期(剩余约1个月),但截至目前仅累计增持A股10万股,成交金额约383.84万元,距离5000万元的最低目标尚有超过4500万元的缺口。根据该计划,熊俊计划自2025年4月12日起12个月内,通过A股和H股市场增持...
Source Link2026年3月10日盘后,君实生物(SH688180)发布公告,披露了公司控股股东、实际控制人之一兼董事长熊俊增持计划的进展。根据公告,熊俊自2025年4月启动的亿元级增持计划已临近到期(剩余约1个月),但截至目前仅累计增持A股10万股,成交金额约383.84万元,距离5000万元的最低目标尚有超过4500万元的缺口。根据该计划,熊俊计划自2025年4月12日起12个月内,通过A股和H股市场增持...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.